Enanta CMO Nathalie Adda to retire Feb 28, 2022; consulting deal signed

ENANTA PHARMACEUTICALS INC

Nathalie Adda, MD, SVP and CMO, announced retirement effective February 28, 2022.
Enanta entered a consulting agreement for up to 3 months post-retirement at $450/hour for up to 70 hours/month.
Existing stock options and restricted stock units will continue to vest during the consulting term.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nathalie Adda

Senior Vice President, Chief Medical Officer

ENTA · ENANTA PHARMACEUTICALS INC

Effective: 2022-02-28
Filed: July 16, 2021, 7:59 PM ET

On July 14, 2021, Nathalie Adda, M.D., Senior Vice President, Chief Medical Officer of Enanta Pharmaceuticals, Inc. (“Enanta”) announced her retirement effective February 28, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathalie Adda departed as Senior Vice President, Chief Medical Officer at ENANTA PHARMACEUTICALS INC.

Action: announced her retirement
Role: Senior Vice President, Chief Medical Officer

Exact text from the filing

On July 14, 2021, Nathalie Adda, M.D., Senior Vice President, Chief Medical Officer of Enanta Pharmaceuticals, Inc. (“Enanta”) announced her retirement effective February 28, 2022 (the “Effective Date”).

View on SEC.gov

ENANTA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001564590-21-036895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.